You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrans-2-Phenylcyclopropylamine
Accession NumberDB02665  (EXPT03088)
TypeSmall Molecule
GroupsExperimental
DescriptionA propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightAverage: 134.1983
Monoisotopic: 134.096974389
Chemical FormulaC9H12N
InChI KeyInChIKey=AELCINSCMGFISI-DTWKUNHWSA-O
InChI
InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/p+1/t8-,9+/m0/s1
IUPAC Name
(1R,2S)-2-phenylcyclopropan-1-aminium
SMILES
[NH3+][C@@H]1C[[email protected]]1C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassAralkylamines
Direct ParentAralkylamines
Alternative Parents
Substituents
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Quaternary ammonium salt
  • Hydrocarbon derivative
  • Organic cation
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9819
Blood Brain Barrier+0.9453
Caco-2 permeable+0.7871
P-glycoprotein substrateNon-substrate0.8338
P-glycoprotein inhibitor INon-inhibitor0.9558
P-glycoprotein inhibitor IINon-inhibitor0.9827
Renal organic cation transporterNon-inhibitor0.8684
CYP450 2C9 substrateNon-substrate0.7997
CYP450 2D6 substrateNon-substrate0.8768
CYP450 3A4 substrateNon-substrate0.7287
CYP450 1A2 substrateInhibitor0.8593
CYP450 2C9 inhibitorNon-inhibitor0.8734
CYP450 2D6 inhibitorNon-inhibitor0.6988
CYP450 2C19 inhibitorInhibitor0.8154
CYP450 3A4 inhibitorNon-inhibitor0.9587
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6521
Ames testNon AMES toxic0.9213
CarcinogenicityNon-carcinogens0.721
BiodegradationReady biodegradable0.8237
Rat acute toxicity2.4558 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9604
hERG inhibition (predictor II)Non-inhibitor0.9333
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0104 mg/mLALOGPS
logP-1.6ALOGPS
logP1.34ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area27.64 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity52.99 m3·mol-1ChemAxon
Polarizability15.83 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Vithal Jagannath Rajadhyaksha, “Method of synthesis of trans-2-phenylcyclopropylamine.” U.S. Patent US4016204, issued October, 1964.

US4016204
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Trans-2-Phenylcyclopropylamine.
AcarboseTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Acarbose.
AcebutololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Trans-2-Phenylcyclopropylamine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Trans-2-Phenylcyclopropylamine.
adipiplonThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Agomelatine.
AlbiglutideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Albiglutide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trans-2-Phenylcyclopropylamine.
AliskirenTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.
AlogliptinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Trans-2-Phenylcyclopropylamine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trans-2-Phenylcyclopropylamine.
AlprenololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Alprenolol.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Trans-2-Phenylcyclopropylamine.
AmbrisentanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ambrisentan.
AmineptineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Amineptine.
AmisulprideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amisulpride.
AmitriptylineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trans-2-Phenylcyclopropylamine.
AmlodipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Trans-2-Phenylcyclopropylamine.
AmoxapineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Trans-2-Phenylcyclopropylamine.
AmperozideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amperozide.
AmphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Amphetamine.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Trans-2-Phenylcyclopropylamine.
ApraclonidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Apraclonidine.
ArbutamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Arformoterol.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trans-2-Phenylcyclopropylamine.
ArticaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Asenapine.
AtenololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Atenolol.
AtomoxetineTrans-2-Phenylcyclopropylamine may increase the central neurotoxic activities of Atomoxetine.
AtropineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Atropine.
AzaperoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Azaperone.
AzelastineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trans-2-Phenylcyclopropylamine.
BaclofenThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Baclofen.
BambuterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Bambuterol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Trans-2-Phenylcyclopropylamine.
BenazeprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Benazepril.
BendroflumethiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bendroflumethiazide.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Trans-2-Phenylcyclopropylamine.
BenzphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Benzyl alcohol.
BepridilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bepridil.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Trans-2-Phenylcyclopropylamine.
BetaxololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Betaxolol.
BethanidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bethanidine.
BezafibrateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Bezafibrate.
BimatoprostTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bimatoprost.
BisoprololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bisoprolol.
BosentanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bosentan.
BretyliumTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.
BrimonidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trans-2-Phenylcyclopropylamine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Trans-2-Phenylcyclopropylamine.
BrompheniramineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trans-2-Phenylcyclopropylamine.
BupranololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trans-2-Phenylcyclopropylamine.
BupropionTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Trans-2-Phenylcyclopropylamine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trans-2-Phenylcyclopropylamine.
ButacaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Trans-2-Phenylcyclopropylamine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trans-2-Phenylcyclopropylamine.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Trans-2-Phenylcyclopropylamine.
CanagliflozinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Canagliflozin.
CandesartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candesartan.
CandoxatrilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candoxatril.
CaptoprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Trans-2-Phenylcyclopropylamine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Trans-2-Phenylcyclopropylamine.
CarisoprodolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Carisoprodol.
CarteololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Carteolol.
CarvedilolTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Carvedilol.
CeliprololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Celiprolol.
CetirizineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Trans-2-Phenylcyclopropylamine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trans-2-Phenylcyclopropylamine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Trans-2-Phenylcyclopropylamine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trans-2-Phenylcyclopropylamine.
ChlorothiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Chlorphenamine.
ChlorphentermineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trans-2-Phenylcyclopropylamine.
ChlorpropamideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trans-2-Phenylcyclopropylamine.
ChlorthalidoneTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Chlorzoxazone.
CilazaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cilazapril.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trans-2-Phenylcyclopropylamine.
CirazolineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Cirazoline.
CitalopramTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Citalopram.
ClemastineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Trans-2-Phenylcyclopropylamine.
ClenbuterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clenbuterol.
ClidiniumThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with clomethiazole.
ClomipramineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Trans-2-Phenylcyclopropylamine.
ClonazepamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clonazepam.
ClonidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Trans-2-Phenylcyclopropylamine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trans-2-Phenylcyclopropylamine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Trans-2-Phenylcyclopropylamine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Trans-2-Phenylcyclopropylamine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trans-2-Phenylcyclopropylamine.
CryptenamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cryptenamine.
CyclizineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Cyclizine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.
CyclothiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cyclothiazide.
CyproheptadineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Cyproheptadine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Trans-2-Phenylcyclopropylamine.
DantroleneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dantrolene.
DapagliflozinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trans-2-Phenylcyclopropylamine.
DapoxetineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Dapoxetine.
DebrisoquinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Debrisoquin.
deramciclaneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with deramciclane.
DeserpidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Deserpidine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Trans-2-Phenylcyclopropylamine.
DesipramineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Trans-2-Phenylcyclopropylamine.
DesloratadineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Desloratadine.
DesvenlafaxineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trans-2-Phenylcyclopropylamine.
DexmethylphenidateTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trans-2-Phenylcyclopropylamine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trans-2-Phenylcyclopropylamine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Trans-2-Phenylcyclopropylamine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Trans-2-Phenylcyclopropylamine.
DiazoxideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Diazoxide.
DiethylpropionTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Diethylpropion.
DifenoxinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trans-2-Phenylcyclopropylamine.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Trans-2-Phenylcyclopropylamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trans-2-Phenylcyclopropylamine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trans-2-Phenylcyclopropylamine.
DiltiazemTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Trans-2-Phenylcyclopropylamine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trans-2-Phenylcyclopropylamine.
DipivefrinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dipivefrin.
DisopyramideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dobutamine.
DomperidoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Doramectin.
DorzolamideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Dorzolamide.
DosulepinTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Dosulepin.
DoxapramTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Doxapram.
DoxazosinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Doxazosin.
DoxepinTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Trans-2-Phenylcyclopropylamine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.
DoxylamineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Trans-2-Phenylcyclopropylamine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Trans-2-Phenylcyclopropylamine.
DroxidopaThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Droxidopa.
DulaglutideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trans-2-Phenylcyclopropylamine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Trans-2-Phenylcyclopropylamine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Efavirenz.
EfonidipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.
EmpagliflozinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Empagliflozin.
EnalaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Enalapril.
EnalaprilatTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Enalaprilat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Trans-2-Phenylcyclopropylamine.
EntacaponeThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Entacapone.
EphedraThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ephedra.
EpinephrineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Epinephrine.
EpoprostenolTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Epoprostenol.
EprosartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Eprosartan.
ErgotamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Ergotamine.
EscitalopramTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Escitalopram.
EsmirtazapineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Esmirtazapine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Trans-2-Phenylcyclopropylamine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trans-2-Phenylcyclopropylamine.
EthanolTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Trans-2-Phenylcyclopropylamine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trans-2-Phenylcyclopropylamine.
EthosuximideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trans-2-Phenylcyclopropylamine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trans-2-Phenylcyclopropylamine.
EtidocaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Trans-2-Phenylcyclopropylamine.
EtoperidoneTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Trans-2-Phenylcyclopropylamine.
ExenatideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Felbamate.
FelodipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Trans-2-Phenylcyclopropylamine.
FenfluramineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Fenfluramine.
FenoldopamTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fenoldopam.
FenoterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trans-2-Phenylcyclopropylamine.
FexofenadineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Trans-2-Phenylcyclopropylamine.
FlunarizineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trans-2-Phenylcyclopropylamine.
FluoxetineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Trans-2-Phenylcyclopropylamine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trans-2-Phenylcyclopropylamine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trans-2-Phenylcyclopropylamine.
FluspirileneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluticasone Propionate.
FluvoxamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trans-2-Phenylcyclopropylamine.
FormoterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Formoterol.
FosinoprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fospropofol.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trans-2-Phenylcyclopropylamine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Trans-2-Phenylcyclopropylamine.
GliclazideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Gliclazide.
GlimepirideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Glimepiride.
GlipizideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Trans-2-Phenylcyclopropylamine.
GlyburideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Glyburide.
GuanabenzTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanabenz.
GuanadrelTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanadrel.
GuanethidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanethidine.
GuanfacineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trans-2-Phenylcyclopropylamine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Trans-2-Phenylcyclopropylamine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trans-2-Phenylcyclopropylamine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Trans-2-Phenylcyclopropylamine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Trans-2-Phenylcyclopropylamine.
HexamethoniumTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hexamethonium.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Trans-2-Phenylcyclopropylamine.
HydralazineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Hydrocodone.
HydroflumethiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.
HydroxyzineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Iloperidone.
ImipramineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Trans-2-Phenylcyclopropylamine.
IndacaterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Indacaterol.
IndalpineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Indalpine.
IndapamideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Indapamide.
IndenololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Indenolol.
IndoraminTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Indoramin.
Insulin AspartTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Lispro.
IrbesartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Irbesartan.
IsoetarineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trans-2-Phenylcyclopropylamine.
IsomethepteneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Isoprenaline.
IsradipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Isradipine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trans-2-Phenylcyclopropylamine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trans-2-Phenylcyclopropylamine.
KetobemidoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ketobemidone.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Trans-2-Phenylcyclopropylamine.
LabetalolTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Labetalol.
LacidipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lacidipine.
LamotrigineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lamotrigine.
LanreotideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Lanreotide.
LatanoprostTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Latanoprost.
LercanidipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lercanidipine.
LevetiracetamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Trans-2-Phenylcyclopropylamine.
LevocabastineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trans-2-Phenylcyclopropylamine.
LevomilnacipranTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Levomilnacipran.
LevonordefrinTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Levonordefrin.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trans-2-Phenylcyclopropylamine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trans-2-Phenylcyclopropylamine.
LinezolidThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Linezolid.
LiraglutideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Trans-2-Phenylcyclopropylamine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Trans-2-Phenylcyclopropylamine.
LofentanilThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lofentanil.
LofexidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lofexidine.
LoratadineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trans-2-Phenylcyclopropylamine.
LosartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trans-2-Phenylcyclopropylamine.
Lu AA21004Trans-2-Phenylcyclopropylamine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Trans-2-Phenylcyclopropylamine.
LurasidoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lurasidone.
MacitentanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Macitentan.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Magnesium Sulfate.
ManidipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trans-2-Phenylcyclopropylamine.
MecamylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Mecamylamine.
MecaserminTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Trans-2-Phenylcyclopropylamine.
MelperoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Melperone.
MephentermineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trans-2-Phenylcyclopropylamine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trans-2-Phenylcyclopropylamine.
MequitazineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trans-2-Phenylcyclopropylamine.
MetaraminolTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Metaxalone.
MetforminTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trans-2-Phenylcyclopropylamine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Trans-2-Phenylcyclopropylamine.
MethamphetamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Trans-2-Phenylcyclopropylamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Trans-2-Phenylcyclopropylamine.
MethoxamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Methoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trans-2-Phenylcyclopropylamine.
MethsuximideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methsuximide.
MethyldopaThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methyldopa.
Methylene blueTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Methylene blue.
MethylphenidateTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Trans-2-Phenylcyclopropylamine.
MetipranololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metipranolol.
MetolazoneTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metolazone.
MetoprololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metoprolol.
MetyrosineTrans-2-Phenylcyclopropylamine may increase the sedative activities of Metyrosine.
MianserinTrans-2-Phenylcyclopropylamine may increase the neurotoxic activities of Mianserin.
MibefradilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Mibefradil.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Trans-2-Phenylcyclopropylamine.
MidodrineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Midodrine.
MifepristoneTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Mifepristone.
MiglitolTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Miglitol.
MilnacipranTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.
MinoxidilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Minoxidil.
MirtazapineTrans-2-Phenylcyclopropylamine may increase the central neurotoxic activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Trans-2-Phenylcyclopropylamine.
MoclobemideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Moclobemide.
MoexiprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Trans-2-Phenylcyclopropylamine.
MorphineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Morphine.
MoxonidineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Moxonidine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.
NabiloneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Nabilone.
NadololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trans-2-Phenylcyclopropylamine.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.
NateglinideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Nateglinide.
NebivololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nebivolol.
NicardipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nicardipine.
NicorandilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nicorandil.
NiguldipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Niguldipine.
NilvadipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nilvadipine.
NimodipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nimodipine.
NisoldipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trans-2-Phenylcyclopropylamine.
NitrendipineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitrendipine.
NitroprussideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Nitrous oxide.
NorepinephrineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Norepinephrine.
NormethadoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Normethadone.
NortriptylineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trans-2-Phenylcyclopropylamine.
OctreotideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Octreotide.
OlanzapineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Trans-2-Phenylcyclopropylamine.
OlmesartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Olopatadine.
OmapatrilatTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Omapatrilat.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Trans-2-Phenylcyclopropylamine.
OpiumThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Opium.
OrciprenalineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Orciprenaline.
OrphenadrineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Trans-2-Phenylcyclopropylamine.
OsanetantThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trans-2-Phenylcyclopropylamine.
OxprenololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trans-2-Phenylcyclopropylamine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Trans-2-Phenylcyclopropylamine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trans-2-Phenylcyclopropylamine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trans-2-Phenylcyclopropylamine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trans-2-Phenylcyclopropylamine.
ParaldehydeTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Trans-2-Phenylcyclopropylamine.
PargylineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pargyline.
ParoxetineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Paroxetine.
PasireotideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Pasireotide.
PenbutololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Penbutolol.
PentamidineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trans-2-Phenylcyclopropylamine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trans-2-Phenylcyclopropylamine.
PentoliniumTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pentolinium.
PerampanelThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Perampanel.
PergolideThe metabolism of Pergolide can be decreased when combined with Trans-2-Phenylcyclopropylamine.
PerindoprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trans-2-Phenylcyclopropylamine.
PethidineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trans-2-Phenylcyclopropylamine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trans-2-Phenylcyclopropylamine.
PhenoxybenzamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenoxyethanol.
PhentermineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Phentermine.
PhentolamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Phentolamine.
PhenylephrineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenylpropanolamine.
PhenytoinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenytoin.
PholcodinePholcodine may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Trans-2-Phenylcyclopropylamine.
PinacidilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pinacidil.
PindololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pindolol.
PioglitazoneTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pirbuterol.
PizotifenTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Pizotifen.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Trans-2-Phenylcyclopropylamine.
PolythiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pomalidomide.
PramipexoleTrans-2-Phenylcyclopropylamine may increase the sedative activities of Pramipexole.
PramlintideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Trans-2-Phenylcyclopropylamine.
PrazosinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Prazosin.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trans-2-Phenylcyclopropylamine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Trans-2-Phenylcyclopropylamine.
PrimidoneThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Trans-2-Phenylcyclopropylamine.
ProcaterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trans-2-Phenylcyclopropylamine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Trans-2-Phenylcyclopropylamine.
PromethazineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trans-2-Phenylcyclopropylamine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trans-2-Phenylcyclopropylamine.
PropoxycaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Propoxycaine.
PropranololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Propranolol.
ProtriptylineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trans-2-Phenylcyclopropylamine.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Trans-2-Phenylcyclopropylamine.
PSD502The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Trans-2-Phenylcyclopropylamine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trans-2-Phenylcyclopropylamine.
QuinaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Quinapril.
QuinineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ramelteon.
RamiprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trans-2-Phenylcyclopropylamine.
RemikirenTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trans-2-Phenylcyclopropylamine.
RepaglinideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Repaglinide.
RescinnamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Rescinnamine.
ReserpineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Trans-2-Phenylcyclopropylamine.
RiociguatTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Riociguat.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Trans-2-Phenylcyclopropylamine.
RitodrineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ritodrine.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.
RomifidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Romifidine.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Trans-2-Phenylcyclopropylamine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trans-2-Phenylcyclopropylamine.
RosiglitazoneTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Rosiglitazone.
RotigotineTrans-2-Phenylcyclopropylamine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trans-2-Phenylcyclopropylamine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Trans-2-Phenylcyclopropylamine.
SalbutamolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Salmeterol.
SaprisartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Saprisartan.
SaxagliptinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trans-2-Phenylcyclopropylamine.
SelexipagTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Selexipag.
SertindoleThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Sertindole.
SertralineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trans-2-Phenylcyclopropylamine.
SitagliptinTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sitagliptin.
SitaxentanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Sitaxentan.
Sodium oxybateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Sodium oxybate.
SpiraprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Spirapril.
StiripentolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trans-2-Phenylcyclopropylamine.
SulfadiazineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trans-2-Phenylcyclopropylamine.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.
SunitinibTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Trans-2-Phenylcyclopropylamine.
TasimelteonThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tasimelteon.
TelmisartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trans-2-Phenylcyclopropylamine.
TemocaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Temocapril.
TerbutalineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Terbutaline.
TerlipressinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Terlipressin.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Trans-2-Phenylcyclopropylamine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trans-2-Phenylcyclopropylamine.
TetracaineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tetrodotoxin.
TetryzolineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Tetryzoline.
ThalidomideTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Trans-2-Phenylcyclopropylamine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Trans-2-Phenylcyclopropylamine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Trans-2-Phenylcyclopropylamine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trans-2-Phenylcyclopropylamine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Trans-2-Phenylcyclopropylamine.
TiagabineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tiagabine.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Trans-2-Phenylcyclopropylamine.
TianeptineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Tianeptine.
TiboloneTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Tibolone.
TicrynafenTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tiletamine.
TimololTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Timolol.
TizanidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tizanidine.
TolazamideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Tolazamide.
TolazolineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Tolazoline.
TolbutamideTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Topiramate.
TorasemideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Trans-2-Phenylcyclopropylamine.
TrandolaprilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trandolapril.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trans-2-Phenylcyclopropylamine.
TravoprostTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Travoprost.
TrazodoneTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Trans-2-Phenylcyclopropylamine.
TreprostinilTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Treprostinil.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Trans-2-Phenylcyclopropylamine.
TrichlormethiazideTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trans-2-Phenylcyclopropylamine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trans-2-Phenylcyclopropylamine.
TrimazosinTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trimazosin.
TrimethaphanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Trimethaphan.
TrimipramineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Trans-2-Phenylcyclopropylamine.
TriprolidineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Triprolidine.
UnoprostoneTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Unoprostone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Trans-2-Phenylcyclopropylamine.
ValsartanTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Valsartan.
VenlafaxineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Venlafaxine.
VigabatrinThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Vigabatrin.
VilanterolThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Vilanterol.
VilazodoneTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Vilazodone.
VortioxetineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Trans-2-Phenylcyclopropylamine.
XylazineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Xylazine.
XylometazolineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Xylometazoline.
YohimbineThe therapeutic efficacy of Trans-2-Phenylcyclopropylamine can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trans-2-Phenylcyclopropylamine.
ZiconotideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ziconotide.
ZimelidineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Trans-2-Phenylcyclopropylamine.
ZolazepamThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Zolazepam.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Trans-2-Phenylcyclopropylamine.
ZonisamideThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Trans-2-Phenylcyclopropylamine.
ZotepineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Trans-2-Phenylcyclopropylamine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form against all of these substrates.
Gene Name:
PRSS1
Uniprot ID:
P07477
Molecular Weight:
26557.88 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23